SCHEMBL3087344

SCHEMBL3087344

OC[C](c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
MAPK1 P28482 2/20 0.43
CYP3A4 P08684 2/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 3/20 0.43
CES2 O00748 2/20 0.43
ALDH1A1 P00352 2/20 0.43
DAO P14920 1/20 0.43
NAPRT Q6XQN6 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
NCOR2 Q9Y618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27865135 0.85 CES2 (0.56) CES1MAPTMEN1HPGDALOX15
SCHEMBL8110239 0.78 L3MBTL1 (0.46) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL27827492 0.77 TDP1 (0.42) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL8673222 0.75 CES1 (0.43) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL10348963 0.75 CES1 (0.43) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL7034583 0.75 CES1 (0.43) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL15437888 0.75 CES1 (0.43) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL2295034 0.75 KMT2A (0.55) CES1TDP1MAPTKDM4EKMT2A
SCHEMBL144605 0.73 CES1 (0.42) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL219736 0.73 ATM (0.54) CES1TDP1MAPK1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US claimed
EP-2061449-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES Leo Pharma A/S (DK) 2009-05-27 EP claimed
WO-2008019690-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2008-02-21 WO claimed
EP-1042291-B1 ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS KLINGE CO CHEM PHARM FAB (DE) 2005-07-13 EP claimed
CN-109863151-A Fused tricyclic pyridazinone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2019-06-07 CN disclosed
EP-3155687-A1 PRELITHIATION SOLUTIONS FOR LITHIUM-ION BATTERIES Amprius, Inc. (US) 2017-04-19 EP disclosed
US-9581905-B2 Composition for film formation, resist underlayer film and forming method thereof, pattern-forming method and compound JSR CORPORATION (JP) 2017-02-28 US disclosed
US-20160085152-A1 COMPOSITION FOR FILM FORMATION, RESIST UNDERLAYER FILM AND FORMING METHOD THEREOF, PATTERN-FORMING METHOD AND COMPOUND JSR CORPORATION (JP) 2016-03-24 US disclosed
US-20150364795-A1 PRELITHIATION SOLUTIONS FOR LITHIUM-ION BATTERIES SILICON VALLEY BANK 2015-12-17 US disclosed
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US disclosed
US-20100227896-A1 USE OF VITAMIN PP COMPOUNDS ASTELLAS DEUTSCHLAND GMBH (DE) 2010-09-09 US disclosed
EP-2061449-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES Leo Pharma A/S (DK) 2009-05-27 EP disclosed
WO-2008019690-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2008-02-21 WO disclosed
EP-1079832-B1 USE OF VITAMIN PP COMPOUNDS KLINGE CO CHEM PHARM FAB (DE) 2005-11-30 EP disclosed
EP-1079832-A1 USE OF VITAMIN PP COMPOUNDS Klinge Pharma GmbH (DE) 2001-03-07 EP disclosed
WO-1999053920-A1 USE OF VITAMIN PP COMPOUNDS KLINGE PHARMA GMBH (DE) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160085152-A1 COMPOSITION FOR FILM FORMATION, RESIST UNDERLAYER FILM AND FORMING METHOD THEREOF, PATTERN-FORMING METHOD AND COMPOUND RER1, RRS1, RO60 CES1 3145/4885TDP1 1789/4885MAPK1 2803/4885
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES C1R, C3AR1, PTH1R CES1 54/4885TDP1 4767/4885MAPK1 3088/4885
US-20100227896-A1 USE OF VITAMIN PP COMPOUNDS PNPO, NAMPT, NAPRT CES1 840/4885TDP1 1717/4885MAPK1 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.